Filing Flows › Serina Therapeutics (SER) › Q2 2025
Serina Therapeutics (SER) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 11, 2025
Serina Therapeutics (SER) reported revenue of $130K for the second quarter 2025 (Q2 2025), +155% from a year earlier.
Serina Therapeutics, Q2 2025: revenue $130K (+155% year over year), net loss $6.5M, operating cash flow −$3.8M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $130K | — | +155% |
| Operating profit | −$5.6M | — | — |
| Net earnings | −$6.5M | — | — |
| Operating cash flow | −$3.8M | — | — |
What changed
Revenue was $130K in Q2 2025, up 155% year over year.
Operating costs exceeded revenue by $5.6M, an operating margin of -4280.8%. Total costs grew 45% against revenue growth of 155%. The fastest-growing cost line was Research & development (+98%). The quarter ended with a net loss of $6.5M. Minority interests bore $14K of it: to shareholders the quarter was a loss of $6.4M.
Operating cash flow was −$3.8M. Non-cash charges added back $16K of depreciation and amortization and $890K of share-based compensation. Working capital and other items added $1.8M. Capital expenditures of $46K exceeded it, leaving free cash flow of −$3.8M.
Questions
What was Serina Therapeutics' revenue in the second quarter 2025?
Serina Therapeutics (SER) reported revenue of $130K for the second quarter 2025 (Q2 2025), +155% from a year earlier.